Navigation Links
EpiDerm's Skin Irritation Test Fully Validated in European Union
Date:12/17/2008

Significant milestone met in development and validation of non-animal alternative test methods

ASHLAND, Mass., Dec. 17 /PRNewswire/ -- MatTek Corporation today announced that the ECVAM Scientific Advisory Committee (ESAC) endorsed the scientific validity of the Modified EpiDerm Skin Irritation Test (SIT) at its November meeting. ESAC concluded that the Modified EpiDerm SIT has sufficient accuracy and reliability for the prediction of skin irritating and non-irritating test substances.

The Updated EpiDerm SIT is a modification of the previously validated EpiDerm skin irritation method (ESAC Statement, April 2007). The major modification is an extended chemical exposure time from 15 to 60 minutes that reflects the robust barrier function of the EpiDerm model. The new exposure time provides an improved sensitivity of the in vitro EpiDerm SIT and better correlation with in vivo Draize rabbit skin irritation results.

The Modified EpiDerm SIT eliminates the need for animal testing when used to determine skin irritation potential of chemicals, including raw cosmetic materials. This development allows companies world-wide to comply with new European Union (EU) REACH legislation as well as the EU directive on the protection and welfare of animals used for experimental and other scientific purposes. This directive (EU 86/609) prohibits the use of animals in experiments if a validated alternative is available.

The Modified EpiDerm SIT will also be of great benefit to the Cosmetic Industry because testing of cosmetic raw materials in animals will be prohibited in the EU beginning March 2009 (7th Amendment of EU Cosmetic Directive).

John Sheasgreen, MatTek's President, added, "The validation of the Modified EpiDerm SIT involved multiple successful transatlantic tissue shipments from MatTek's US production facility to EU testing laboratories. The abilit
'/>"/>

SOURCE MatTek Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
5. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
6. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
7. YMed, Inc. Successfully Completes First Clinical Cases With Innovative VascuTraK(TM) II PTA Dilatation Catheter
8. New Study Shows LEVITRA Successfully Treats Erectile Dysfunction (ED) in Men with Dyslipidemia, Including High Cholesterol
9. NanoBio Corporation Successfully Completes Phase 2b Study in Herpes Labialis
10. Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
11. Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2009)...ics Based On Naturally Resected tRNA Synthetases ...oPharma, a subsidiary of aTyr Pharma in Hong Kong,...plication on proprietary, naturally occurring, res...etases are universal and essential components of p... human synthetases have naturally occurring resect...
(Date:6/26/2009)..., June 27, 2009 Takeda Pharmaceuti...t Takeda Global Research & Development Center,...ary received on June 26 (U.S. time) a complete res...ation (FDA) regarding the Company,s New Drug Appli...l peptidase IV (DPP-4) inhibitor under investigati...
(Date:6/25/2009)... to Attend First National Symposium - , , CORTL...nal symposium designed to explore the health impac...York City when thirteen top experts gather to pres...elds. The SUNY Youth Sports Institute will gather...at the $5 billion-a-year energy drink industry has...
(Date:6/24/2009)...n a revolutionary healthcare finding, a peer-revie...l of Nutrition (a Cambridge University Journal),...rol and triglycerides, control body weight, and in...ical study was conducted on rats and showed that t... 24 months versus a 50% survival rate for the cont...
Breaking Medicine Technology:Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Files Three Patent Applications 2Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Files Three Patent Applications 3Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes 2SUNY Youth Sports Institute Convenes Top Experts in NYC Next Week to Present Research & Analysis on Energy Drink Health Impacts 2SUNY Youth Sports Institute Convenes Top Experts in NYC Next Week to Present Research & Analysis on Energy Drink Health Impacts 3SUNY Youth Sports Institute Convenes Top Experts in NYC Next Week to Present Research & Analysis on Energy Drink Health Impacts 4New Study Shows that Prebiotics, as Used by Jackson GI Medical, Increases Lifespan by 33% 2Aware Inc Announces Q1 09 Earnings Conference Call 8152 1Aware Inc Announces Q1 09 Earnings Conference Call 8152 2New cow genome sequence released 11697 1New cow genome sequence released 11697 2Scientists moving closer to artificial noses 11695 1Scientists moving closer to artificial noses 11695 2Scientists moving closer to artificial noses 11695 3Dont Lower Age for Cervical Cancer Test Study Urges 43454 1Dont Lower Age for Cervical Cancer Test Study Urges 43454 2
... ROCKVILLE, Md., May 2, 2007-The U.S. Food and Dr...t="_blank" href=,"http://www.fda.gov/oc/initiative... Opportunities for Generic Drugs " report identify...at impede the development,of generic versions of c...Critical Path Initiative,established in 2004 to d...
... CAMBRIDGE, England, 26th April 2007 - CeNeS Phar...opharmaceutical company, today,announces that the ...as approved its Investigational New Drug (IND) app...6-glucuronide (M6G), its novel,drug for the treatm...eS announced results of a Phase III study of M6G i...
Other Medicine Technology:New Critical Path Report Highlights Research Needed to Foster,Generic Drug Development 2FDA approves IND on Lead Product M6G 2
(Date:7/2/2009)...CHICAGO, July 2 Recent ...ysician credentials and ensuring that physicians m...e, according to the American Board of Medical Spec...24 Member Boards in their efforts to develop and i...r the evaluation and certification of physician sp...
(Date:7/2/2009)...LITTLE SILVER, N.J., July 2 Dr Dan... is coordinating a new study to measure the effect...ent of acute EKC -- a common, worldwide, highly co...ith the potential for long term visual impairment ...s around the world are invited to register to part...
(Date:7/2/2009)...ctive conservation can help reduce threat, expert...ws) -- Cancer is a major threat to certain species...ealth monitoring, researchers say. , "Cancer is...counting for more than 10 percent of human deaths....nimals at similar rates," lead author Denise McAlo...
(Date:7/2/2009)...rtain mutations in the DNA of the hepatitis B viru...er cancer and may help predict which patients with...se, according to a large meta-analysis in the Jou...online July 2. , HBV infection is a known cause ... form of liver cancer. Previous studies have looke...
Breaking Medicine News(10 mins):Health News:Seek Out Credentials Before Choosing a Physician - Is Your Cardiologist Board Certified in Cardiovascular Disease? 2Health News:Seek Out Credentials Before Choosing a Physician - Is Your Cardiologist Board Certified in Cardiovascular Disease? 3Health News:Seek Out Credentials Before Choosing a Physician - Is Your Cardiologist Board Certified in Cardiovascular Disease? 4Health News:Ophthalmologists Invited To Participate in Betadine for EKC Treatment Study 2Health News:Cancer Endangers Some Wildlife Species 2
...ut off just with the news and then following it up...disrupts their world completely. However, research... disruptive way of treating these cancers. Radiati...pital// in Detroit said that with a new type of tr...
... Cancer reported a study by the researchers of the...at regular mammography screening for women in thei...rlier stage. This could facilitate the use of more... options.// Sandra Buseman, MD, lead author of the...
...t "erythropoietin", a genetically engineered drug,...fe-threatening anaemia among patients who have bee...d in the late 1980s and is used to treat patients ...Red Cell Aphasia or PRCA usually occurs in vanishi...
... may progress as a disease is the human immunodefi...ody that it confounds the already-weakened immune ..., conventional tests used to determine how well a ...fense can be misleading, the researchers, from Har...
Other Medicine News:Health News:Breast Cancer in younger women can be detected at an early stage by mammograms 2Health News:Success of HIV may depend in its mutations 2
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve
... order products are offered as 1-piece or modular,...truments may be customized with handles of choice ... flush ports. Many standard patterns are available...affect delivery times. , Please Note: Individual...
... order products are offered as 1-piece or modular,...truments may be customized with handles of choice ... flush ports. Many standard patterns are available...affect delivery times. , Please Note: Individual...
... order products are offered as 1-piece or modular,...truments may be customized with handles of choice ... flush ports. Many standard patterns are available...affect delivery times. , Please Note: Individual...
Medicine Products: